NCT01427205: Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC) |
|
|
| Withdrawn | 2 | 0 | US | Cetuximab, C225, Erbitux, IMC-C225, OSI-906, Placebo, sugar pill | M.D. Anderson Cancer Center, OSI Pharmaceuticals | Head and Neck Cancer | 06/16 | | | |
NCT01465815: Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN) |
|
|
| Withdrawn | 1/2 | 0 | US | erlotinib hydrochloride, CP-358,774, erlotinib, OSI-774, linsitinib, OSI-906, placebo, PLCB, radiation therapy, irradiation, radiotherapy, therapy, radiation, therapeutic conventional surgery, laboratory biomarker analysis | OHSU Knight Cancer Institute, National Cancer Institute (NCI) | Recurrent Skin Cancer, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Squamous Cell Carcinoma of the Skin, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity | 09/13 | 09/13 | | |
